These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1101 related items for PubMed ID: 19805690
1. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G. J Clin Oncol; 2009 Nov 01; 27(31):5168-74. PubMed ID: 19805690 [Abstract] [Full Text] [Related]
2. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]. zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H. Klin Padiatr; 2000 Nov 01; 212(4):169-73. PubMed ID: 10994545 [Abstract] [Full Text] [Related]
3. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA. J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891 [Abstract] [Full Text] [Related]
4. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi A, Miniero R, Di Tullio MT, Lo Nigro L, Pession A, Rondelli R, Messina C, Santoro N, Mori PG, De Rossi G, Tamaro P, Silvestri D, Biondi A, Basso G, Masera G. Haematologica; 1998 Sep 20; 83(9):791-9. PubMed ID: 9825576 [Abstract] [Full Text] [Related]
5. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group. J Clin Oncol; 2009 Jan 20; 27(3):377-84. PubMed ID: 19064980 [Abstract] [Full Text] [Related]
6. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. Aricò M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, Locatelli F, Lo Nigro L, Luciani M, Messina C, Micalizzi C, Parasole R, Pession A, Santoro N, Testi AM, Silvestri D, Basso G, Masera G, Conter V. J Clin Oncol; 2008 Jan 10; 26(2):283-9. PubMed ID: 18182669 [Abstract] [Full Text] [Related]
8. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. MRD-AML-BFM Study GroupDepartment of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany. langebrake.claudia@mh-hannover.de, Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F, Zimmermann M, Reinhardt D. J Clin Oncol; 2006 Aug 01; 24(22):3686-92. PubMed ID: 16877738 [Abstract] [Full Text] [Related]
9. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. Ryan J, Quinn F, Meunier A, Boublikova L, Crampe M, Tewari P, O'Marcaigh A, Stallings R, Neat M, O'Meara A, Breatnach F, McCann S, Browne P, Smith O, Lawler M. Br J Haematol; 2009 Jan 01; 144(1):107-15. PubMed ID: 19016726 [Abstract] [Full Text] [Related]
10. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Thörn I, Forestier E, Botling J, Thuresson B, Wasslavik C, Björklund E, Li A, Lindström-Eriksson E, Malec M, Grönlund E, Torikka K, Heldrup J, Abrahamsson J, Behrendtz M, Söderhäll S, Jacobsson S, Olofsson T, Porwit A, Lönnerholm G, Rosenquist R, Sundström C. Br J Haematol; 2011 Mar 01; 152(6):743-53. PubMed ID: 21250970 [Abstract] [Full Text] [Related]
11. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD, Australian and New Zealand Children's Oncology Group. Br J Haematol; 2009 Aug 01; 146(3):292-9. PubMed ID: 19500099 [Abstract] [Full Text] [Related]
12. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia]. Raciborska A, Wypych A, Rokicka-Milewska R, Siedlecki JA, Kulik J. Przegl Lek; 2004 Aug 01; 61 Suppl 2():62-6. PubMed ID: 15686049 [Abstract] [Full Text] [Related]
13. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). Stark B, Avigad S, Luria D, Manor S, Reshef-Ronen T, Avrahami G, Yaniv I. Pediatr Blood Cancer; 2009 Jan 01; 52(1):20-5. PubMed ID: 19006253 [Abstract] [Full Text] [Related]
14. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, Mann G, Hählen K, Göbel U, Klingebiel T, Ludwig WD, Henze G. J Clin Oncol; 2005 Nov 01; 23(31):7942-50. PubMed ID: 16258094 [Abstract] [Full Text] [Related]
15. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Zhao XS, Liu YR, Zhu HH, Xu LP, Liu DH, Liu KY, Huang XJ. Ann Hematol; 2012 Feb 01; 91(2):183-92. PubMed ID: 21710165 [Abstract] [Full Text] [Related]
16. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Lewandowski K, Kielbinski M, Czyz A, Balana-Nowak A, Król M, Skotnicki AB, Jedrzejczak WW, Warzocha K, Lange A, Hellmann A. Br J Haematol; 2008 Jun 01; 142(2):227-37. PubMed ID: 18492099 [Abstract] [Full Text] [Related]
17. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97]. Janka-Schaub GE, Harms DO, den Boer ML, Veerman AJ, Pieters R. Klin Padiatr; 1999 Jun 01; 211(4):233-8. PubMed ID: 10472556 [Abstract] [Full Text] [Related]
18. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood. Mussolin L, Pillon M, Conter V, Piglione M, Lo Nigro L, Pierani P, Micalizzi C, Buffardi S, Basso G, Zanesco L, Rosolen A. J Clin Oncol; 2007 Nov 20; 25(33):5254-61. PubMed ID: 18024872 [Abstract] [Full Text] [Related]
19. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G. Eur J Cancer; 2013 Apr 20; 49(6):1346-55. PubMed ID: 23265714 [Abstract] [Full Text] [Related]
20. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia]. Ye QD, Gu LJ, Tang JY, Xue HL, Chen J, Pan C, Chen J, Dong L, Zhou M, Jiang LM. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun 20; 10(3):333-6. PubMed ID: 18554462 [Abstract] [Full Text] [Related] Page: [Next] [New Search]